Elif Hindié
PUPH
/ Contact
www.orcid.org/0000-0003-2101-5626
Publications
-
Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlighting 43Sc, 61Cu and 45Ti
EJNMMI Phys. 2024-11-22. 11(1)
10.1186/s40658-024-00699-z -
Membrane and Nuclear Absorbed Doses from 177Lu and 161Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study
J Nucl Med. 2023-06-15. : jnumed.123.265509.
10.2967/jnumed.123.265509 -
Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
JCO. 2023-05-31.
10.1200/JCO.23.00686 -
Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
Cancers. 2023-04-18. 15(8) : 2345.
10.3390/cancers15082345 -
Design, Synthesis, and Biological Evaluation of the First Radio-Metalated Neurotensin Analogue Targeting Neurotensin Receptor 2
ACS Omega. 2023-02-10. 8(7) : 6994-7004.
10.1021/acsomega.2c07814 -
Risk of Overusing Sentinel Node Biopsy in Patients With Thin Melanoma
JCO. 2022-12-01.
10.1200/JCO.22.01963 -
Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help
JCO. 2022-11-01. 40(31) : 3669-3670.
10.1200/JCO.22.01178 -
Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study
J Nucl Med. 2022-09-02. : jnumed.122.263889.
10.2967/jnumed.122.263889 -
How to explain the sensitivity of DNA double-strand breaks yield to 125I position?
International Journal of Radiation Biology. 2022-03-08. : 1-6.
10.1080/09553002.2022.2047822 -
Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors
Breast Cancer Res Treat. 2021-10-01.
10.1007/s10549-021-06402-5 -
Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma
JCO. 2021-03-10. 39(8) : 943-944.
10.1200/JCO.20.03213 -
Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging
Bioconjugate Chem.. 2020-09-18.
10.1021/acs.bioconjchem.0c00419 -
Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial
JMIR Res Protoc. 2020-09-10. 9(9) : e17850.
10.2196/17850 -
Diagnostic performance of imaging techniques for detecting of local recurrence after prostate brachytherapy
Cancer/Radiothérapie. 2020-07-01. 24(4) : 323-331.
10.1016/j.canrad.2020.03.008 -
Choline PET/CT in Multiple Myeloma
Cancers. 2020-05-28. 12(6) : 1394.
10.3390/cancers12061394 -
Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases
EJNMMI Phys. 2020-05-19. 7(1)
10.1186/s40658-020-00301-2 -
Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides
EJNMMI Res. 2020-03-02. 10(1)
10.1186/s13550-020-0612-8 -
Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial (Preprint)
JMIR. 2020-01-16.
10.2196/preprints.17850 -
Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
EJNMMI Res. 2019-06-03. 9(1)
10.1186/s13550-019-0517-6 -
Parathyroid Scintigraphy
. 2005-10-01.
10.52717/SLPN2034